GT
DNTH icon

Glenmede Trust’s Dianthus Therapeutics DNTH Stock Holding History

Glenmede Trust’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
15,740
+3,270
+26% +$286K 0.01% 654
2026
Q1 		$1.05M Buy
12,470
+6,125
+97% +$355K 0.01% 723
2025
Q4 		$261K Buy
+6,345
New +$246K ﹤0.01% 1201

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Glenmede Trust's DNTH Position: Q2 2026 in Review

Glenmede Trust increased its Dianthus Therapeutics (DNTH) stake by 26% in Q2 2026, buying an estimated $286K and bringing the position to 15,740 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #654.

Glenmede Trust first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Glenmede Trust held 15,740 shares of Dianthus Therapeutics worth $1.53M as of Q2 2026.
  • Glenmede Trust bought 3,270 Dianthus Therapeutics shares in Q2 2026, an estimated $286K.
  • Dianthus Therapeutics made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #654 holding.
  • Glenmede Trust first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.